 Celsion Corporation NASDAQ: CLSN reports interim observations and provides an update on its Phase 12 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 34 ovarian cancer. GEN-1 is a DNA-mediated interleukin-12 IL-12 immunotherapy. 